Globally Grifols develops and produces more than a dozen plasma-derived protein therapies as well as products and IV solutions designed for hospital pharmacies, hospitals and laboratories. Our wide range of therapies and products are distributed through three primary divisions: Bioscience, Diagnostic and Hospital.
As our largest segment of the business, the Bioscience division is committed to discovering, developing and producing plasma-derived protein therapies to treat patients whose diseases in many cases cannot be adequately treated with traditional pharmaceuticals. The essential proteins found in human plasma are used to replace or restore missing proteins among patients who have rare, genetic diseases such as immune deficiencies, autoimmune disorders, bleeding or blood-clotting disorders and genetic emphysema. Our protein therapies are also administered to prevent the onset of life-threatening infections such as rabies, hepatitis and tetanus. Bioscience products are sold in more than 90 countries worldwide.
Our Diagnostic division focuses on researching, developing, manufacturing and marketing in vitro diagnostic products for laboratory analyses, including auto-analyzers and reagents for hospital blood banks and transfusion centers. These innovative diagnostic solutions are sold in the U.S. and more than seventy other countries worldwide.
Our Hospital division supplies a wide range of intravenous solutions for hospital pharmacies and medical devices for surgical procedures. These products are divided into four specialties – IV Therapy, Clinical Nutrition, Hospital Logistics and Medical Devices – and are available in some European and Latin American countries.